A phase II trial ARISE (NCT02985879), which aimed at evaluating tilavonemab in PSP patients, was terminated due to the unsatisfactory results in improving the Progressive Supranuclear Palsy Rating Scale (PSPRS) Total Score, despite the decreased CSF free tau and increased plasma total tau levels [146, 166]. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.